----

----

| [X] | QUARTERLY      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|-----|---------------------------------------------------------------------------------------------|

| [      ] | TRANSITION      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|----------|----------------------------------------------------------------------------------------------|

|                        Delaware                 |                    26-2443288            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (State      or Other Jurisdiction of                                                                                                                                                                                 | (I.R.S.      Employer I.D. No.)                                                                                                                             |
| incorporation      or organization)                                                                                                                                                                                  |                                                                                                                                                        |

----

|                                                                                                                             | Page(s) |
|----------------------------------------------------------------------------------------------------------------------------------|---------|
|                                                                                                                             |    |
| Consolidated      Balance Sheets as of September 30, 2009 (Unaudited) and June 30,      2009                                     | 2       |
|                                                                                                                             |    |
| Consolidated      Statements of Operations and Comprehensive Loss for the Three Months Ended      September 30, 2009 (Unaudited) | 3       |
|                                                                                                                             |    |
| Consolidated      Statements of Cash Flows for the Three Months Ended September 30, 2009      (Unaudited)                        | 4       |
|                                                                                                                             |    |
| Notes      to Financial Statements (Unaudited)                                                                                   | 5-7     |
|                                                                                                                             |    |

----

| JINZANGHUANG      TIBET PHARMACEUTICALS, INC.                                                                                       |   |
|-------------------------------------------------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED      BALANCE SHEETS                                                                                                    |   |
|                                                                                                                                |   |   |   |   |   |   |
|                                                                                                                                |   |   |   |   |   |   |
|                                                                                                                                |   |   |   |   |   |   |
| ASSETS                                                                                                                              |
|                                                                                                                                |   | September      30, |   |   | June      30, |   |
|                                                                                                                                |   | 2009 |   |   | 2009 |   |
|                                                                                                                                |   | (Unaudited) |   |   |   |   |
| CURRENT      ASSETS:                                                                                                                |   |   |   |   |   |   |
|      Cash                                                                                                  |   | $ | 102,138 |   |   | $ | 25,115 |   |
|      Accounts      receivable                                                                              |   |   | 44,010 |   |   |   | 32,759 |   |
|      Inventory                                                                                             |   |   | 155,422 |   |   |   | 326,937 |   |
|      Advance      to supplier                                                                              |   |   | 249,289 |   |   |   | 146,399 |   |
|      Contract      deposit                                                                                 |   |   | 146,700 |   |   |   | - |   |
|      Prepaid      expenses and other sundry current assets                                                 |   |   | 25,124 |   |   |   | 15,830 |   |
| TOTAL      CURRENT ASSETS                                                                                                           |   |   | 722,683 |   |   |   | 547,040 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| PROPERTIES      AND EQUIPMENT, NET OF ACCUMULATED DEPRECIATION AND      AMORTIZATION                                                |   |   | 579,254 |   |   |   | 586,000 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| TOTAL  ASSETS                                                                                                             |   | $ | 1,301,937 |   |   | $ | 1,133,040 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| LIABILITIES      AND STOCKHOLDERS' EQUITY                                                                                           |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| CURRENT      LIABILITIES:                                                                                                           |   |   |   |   |   |   |   |   |
|      Accrued      expenses and other sundry current liabilities                                            |   | $ | 61,405 |   |   | $ | 635,763 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| TOTAL      CURRENT LIABILITIES AND TOTAL LIABILITIES                                                                                |   |   | 61,405 |   |   |   | 635,763 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| STOCKHOLDERS'      EQUITY:                                                                                                          |   |   |   |   |   |   |   |   |
|    Common      stock, $0.001 par value, 300,000,000 shares authorized, 40,645,063      shares issued and outstanding |   |   | 40,645 |   |   |   | 40,645 |   |
|    Additional      paid-in capital                                                                                   |   |   | 1,228,925 |   |   |   | 490,117 |   |
|    Accumulated      deficit                                                                                          |   |   | (93,797 | ) |   |   | (60,009 | ) |
|    Accumulated      other comprehensive income (loss)                                                                |   |   | 1,380 |   |   |   | (3 | ) |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| TOTAL      STOCKHOLDERS' EQUITY OF JINZANGHUANG TIBET PHARMACEUTICALS,      INC.                                                    |   |   | 1,177,153 |   |   |   | 470,750 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| NONCONTROLLING      INTEREST IN SUBSIDIARY                                                                                          |   |   | 63,379 |   |   |   | 26,527 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| TOTAL      STOCKHOLDERS' EQUITY                                                                                                     |   |   | 1,240,532 |   |   |   | 497,277 |   |
|                                                                                                                                |   |   |   |   |   |   |   |   |
| TOTAL      LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                     |   | $ | 1,301,937 |   |   | $ | 1,133,040 |   |

----

| JINZANGHUANG      TIBET PHARMACEUTICALS, INC.                                                                                                               |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED      STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS                                                                                           |   |
| THREE      MONTH ENDED SEPTEMBER, 2009 (1)                                                                                                                  |   |
| (Unaudited)                                                                                                                                                 |   |
|                                                                                                                                                        |   |   |   |   |
|                                                                                                                                                        |   |   |   |   |
| SALES                                                                                                                                                       |   | $ | 224,950 |   |
|                                                                                                                                                        |   |   |   |   |
| COSTS      of SALES                                                                                                                                         |   |   |                       171,856 |   |
|                                                                                                                                                        |   |   |   |   |
| GROSS      PROFIT                                                                                                                                           |   |   |                         53,094 |   |
|                                                                                                                                                        |   |   |   |   |
| COSTS      AND EXPENSES                                                                                                                                     |   |   |   |   |
| General      and Administrative Expenses                                                                                                                    |   |                         84,470 |   |
|                                                                                                                                                        |   |   |   |   |
| LOSS      BEFORE INCOME TAX AND NONCONTROLLING INTEREST INSUBSIDIARY                                                                                        |   |                        (31,376) |   |
|                                                                                                                                                        |   |   |   |   |
| INCOME      TAX                                                                                                                                             |   |   |                           2,236 |   |
|                                                                                                                                                        |   |   |   |   |
| CONSOLIDATED      NET LOSS                                                                                                                                  |   |                        (33,612) |   |
|                                                                                                                                                        |   |   |   |   |
| LESS:      NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS                                                                                              |   |                             176 |   |
|                                                                                                                                                        |   |   |   |   |
| NET      LOSS ATTRIBUTABLE TO JINZANGHUANG TIBET PHARMACEUTICALS,    INC.                                                                                   |   |                        (33,788) |   |
|                                                                                                                                                        |   |   |   |   |
| OTHER      COMPREHENSIVE LOSS                                                                                                                               |   |   |   |
| Foreign      currency translation adjustment                                                                                                                |   |                           1,344 |   |
|                                                                                                                                                        |   |   |   |   |
| COMPREHENSIVE      LOSS                                                                                                                                     |   |   |                        (32,444) |   |
|                                                                                                                                                        |   |   |   |   |
| LESS:      OTHER COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING      INTERESTS                                                                           | $      | 36 |   |
|                                                                                                                                                        |   |   |   |   |
| COMPREHENSIVE      LOSS ATTRIBUTABLE TO JINZANGHUANG TIBET PHARMACEUTICALS,    INC.                                                                         | $      | (32,480) |   |
|                                                                                                                                                        |   |   |   |   |
|                                                                                                                                                        |   |   |   |   |
|                                                                                                                                                        |   |   |   |   |
| Basic      and diluted earnings per common share                                                                                                            | $      | (0.00) |   |
|                                                                                                                                                        |   |   |   |   |
| Weighted      average number of shares outstanding                                                                                                          |   |                   40,645,063 |   |
|                                                                                                                                                        |   |   |   |   |
|                                                                                                                                                        |   |   |   |   |
| (1)      Financial statements for the three months ended September 30, 2008 are not      presented since the      Company was incorporated after that date. |   |   |   |

----

| JINZANGHUANG      TIBET PHARMACEUTICALS, INC.                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CONSOLIDATED      STATEMENTS OF CASH FLOW                                                                                                                   |
| THREE      MONTH ENDED SEPTEMBER, 2009 (1)                                                                                                                  |
| (Unaudited)                                                                                                                                                 |
|                                                                                                                                                        |   |   |   |   |
| OPERATING      ACTIVITIES:                                                                                                                                  |   |   |   |   |
| Net      loss attributable to Jinzanghang Tibet Pharmaceuticals,    Inc.                                                                                    |   | $ | (33,788) |   |
| Adjustments      to reconcile net loss to net cash used in      operating activities:                                                                  |   |   |   |   |
|      Net      income attributable to noncontrolling interests                                                                      |   |   |                         176 |   |
| Cash      used in operating assets and liabilities:                                                                                                         |   |   |   |   |
|      Accounts      receivable                                                                                                      |   |   |                    (11,206) |   |
|      Inventory                                                                                                                     |   |   |                   171,961 |   |
|      Advance      to supplier                                                                                                      |   |   |                  (102,690) |   |
|      Contract      deposit                                                                                                         |   |   |                  (146,700) |   |
|      Prepaid      expenses and other sundry current assets                                                                         |   |   |                     (9,273) |   |
|      Accrued      expenses and other sundry current liabilities                                                                    |   |   |                  (574,328) |   |
| NET      CASH USED IN OPERATING ACTIVITIES                                                                                                                  |   |   |                  (705,848) |   |
|                                                                                                                                                        |   |   |   |   |
| INVESTING      ACTIVITIES:                                                                                                                                  |   |   |   |   |
|     Acquisition      of property and equipment                                                                                          |   |   |                      7,546 |   |
| NET      CASH PROVIDED BY INVESTING ACTIVITIES                                                                                                              |   |   |                      7,546 |   |
|                                                                                                                                                        |   |   |   |   |
| FINANCING      ACTIVITIES:                                                                                                                                  |   |   |   |   |
|      Contribution      from minority interest                                                                                      |   |   |                     36,675 |   |
|      Due      to shareholders                                                                                                      |   |   |                        (861) |   |
|      Capital      contribution                                                                                                     |   |   |                   738,808 |   |
| NET      CASH PROVIDED BY FINANCING ACTIVITIES                                                                                                              |   |   |                   774,622 |   |
|                                                                                                                                                        |   |   |   |   |
| EFFECT      OF EXCHANGE RATE ON CASH                                                                                                                        |   |   |                         702 |   |
|                                                                                                                                                        |   |   |   |   |
| INCREASE      IN CASH                                                                                                                                       |   |   |                     77,022 |   |
|                                                                                                                                                        |   |   |   |   |
| CASH      - BEGINNING OF PERIOD                                                                                                                             |   |   |                     25,115 |   |
|                                                                                                                                                        |   |   |   |   |
| CASH      - END OF PERIOD                                                                                                                                   |   | $ | 102,137 |   |
|                                                                                                                                                        |   |   |   |   |
| Supplemental      disclosures of cash flow information:                                                                                                     |   |   |   |   |
|    Cash      paid for income tax                                                                                                             |   | $ | 8,045 |   |
|                                                                                                                                                        |   |   |   |   |
|                                                                                                                                                        |   |   |   |   |
| (1)      Financial statements for the three months ended September 30, 2008 are not      presented since the      Company was incorporated after that date. |   |

----

|   |
|--------|

----

|   |
|--------|

----

|   |
|--------|

----

| ITEM      2. | MANAGEMENT’S      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF      OPERATIONS |
|--------------|------------------------------------------------------------------------------------------------------|

----

----

|   | · | Relocate      our headquarters from Shangdong to Beijing, where we will have greater      access to marketing channels; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------|

|   | · | Implement      our direct marketing program, including development of an online      presence; |
|--------|--------|------------------------------------------------------------------------------------------------|

|   | · | Acquire      the rights to pharmaceuticals and nutraceuticals that will complement our      existing product line; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------|

|   | · | Carry      on clinical trials of pharmaceuticals required to obtain SFDA      approval; |
|--------|--------|-----------------------------------------------------------------------------------------|

|   | · | Establish      franchisees throughout China; and |
|--------|--------|--------------------------------------------------|

|   | · | Implement      an advertising and marketing program adequate to assure us of substantial      market presence. |
|--------|--------|----------------------------------------------------------------------------------------------------------------|

| ITEM      3. | QUANTITATIVE      AND QUALITATIVE DISCLOSURES ABOUT MARKETRISK |
|--------------|----------------------------------------------------------------|

----

| ITEM      4. | CONTROLS      AND PROCEDURES |
|--------------|------------------------------|

| 31.1 | Rule      13a-14(a) Certification - CEO |
|------|-----------------------------------------|

| 31.2 | Rule      13a-14(a) Certification - CFO |
|------|-----------------------------------------|

| 32 | Rule      13a-14(b) Certifications |
|----|------------------------------------|

----

|                        | JINZANGHUANG      TIBET PHARMACEUTICALS, INC.                                     |
|-----------------------------|-----------------------------------------------------------------------------------|
|                        |                                                                              |
| Date:      December 4, 2009 | By:      /s/ Xue      Bangyi                                                      |
|                        |        Xue      Bangyi, Chief ExecutiveOfficer |

----